AFCo1, a meningococcal B-derived cochleate adjuvant, strongly enhances antibody and T-cell immunity against Plasmodium falciparum merozoite surface protein 4 and 5

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Bracho, Gustavo ^a   Zayas, Caridad ^a   Wang, Lina ^b   Coppel, Ross ^a,b,c  

^a FINLAY INSTITUTE   (Cuba)

^b MONASH UNIVERSITY   (Australia)

^c VAXINE PTY LTD   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT FINLAY COCHLEATE 1; FREUND ADJUVANT; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOLOGICAL ADJUVANT; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 4; MEROZOITE SURFACE PROTEIN 5; MICROORGANISM PROTEIN; PARASITE ANTIGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; INTERLEUKIN 5; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; MEROZOITE SURFACE PROTEIN 4, PLASMODIUM; PROTOZOAL PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DELAYED HYPERSENSITIVITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG POTENCY; DRUG STRUCTURE; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOMODULATION; MALARIA; MEROZOITE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; PLASMODIUM FALCIPARUM; PROTEOLIPOSOME; ANIMAL; BAGG ALBINO MOUSE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPIDEMIC MENINGITIS; GENETICS; HUMAN; IMMUNOLOGY; PHYSIOLOGY; T LYMPHOCYTE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREUND'S ADJUVANT; HUMANS; IMMUNOGLOBULIN G; INTERFERON-GAMMA; INTERLEUKIN-5; MALARIA VACCINES; MEMBRANE PROTEINS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; T-LYMPHOCYTES;

EID: 63849236862     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-35     Document Type: Article

References (54)

1. Population structure and recent evolution of Plasmodium falciparum. SM Rich FJ Ayala, Proc Natl Acad Sci USA 2000 97 6994 7001 10860962
2. Vaccines for preventing malaria. P Graves H Gelband, Cochrane Database Syst Rev 2003 CD000129 12535387
3. Vaccines for preventing malaria (SPf66). P Graves H Gelband, Cochrane Database Syst Rev 2006 CD005966 16625647
4. [The treatment of multiresistant falciparum malaria in Southeast Asia]. R Lasserre, Bull Soc Pathol Exot Filiales 1989 82 94 100 2663211
5. Insecticide-treated nets for preventing malaria in pregnancy. C Gamble JP Ekwaru FO ter Kuile, Cochrane Database Syst Rev 2006 CD003755 16625591
6. Merozoite surface protein 1, immune evasion, and vaccines against asexual blood stage malaria. AA Holder JA Guevara Patino C Uthaipibull SE Syed IT Ling T Scott-Finnigan MJ Blackman, Parassitologia 1999 41 409 14 10697894
7. A malaria merozoite surface protein (MSP1)-structure, processing and function. AA Holder MJ Blackman PA Burghaus JA Chappel IT Ling N McCallum-Deighton S Shai, Mem Inst Oswaldo Cruz 1992 87 Suppl 3 37 42 1343716
8. Merozoite surface protein 8 of Plasmodium falciparum contains two epidermal growth factor-like domains. CG Black T Wu L Wang AR Hibbs RL Coppel, Mol Biochem Parasitol 2001 114 217 26 11378201
9. Close linkage of three merozoite surface protein genes on chromosome 2 of Plasmodium falciparum. VM Marshall W Tieqiao RL Coppel, Mol Biochem Parasitol 1998 94 13 25 9719507
10. Temporal variation of the merozoite surface protein-2 gene of Plasmodium falciparum. D Eisen H Billman-Jacobe VF Marshall D Fryauff RL Coppel, Infect Immun 1998 66 239 46 9423864
11. High levels of serum antibodies to merozoite surface protein 2 of Plasmodium falciparum are associated with reduced risk of clinical malaria in coastal Kenya. SD Polley DJ Conway DR Cavanagh JS McBride BS Lowe TN Williams TW Mwangi K Marsh, Vaccine 2006 24 4233 46 16111789
12. Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. L Wang TL Richie A Stowers DH Nhan RL Coppel, Infect Immun 2001 69 4390 7 11401978
13. Structural and antigenic properties of merozoite surface protein 4 of Plasmodium falciparum. L Wang CG Black VM Marshall RL Coppel, Infect Immun 1999 67 2193 200 10225874
14. Apical location of a novel EGF-like domain-containing protein of Plasmodium falciparum. CG Black L Wang T Wu RL Coppel, Mol Biochem Parasitol 2003 127 59 68 12615336
15. A second merozoite surface protein (MSP-4) of Plasmodium falciparum that contains an epidermal growth factor-like domain. VM Marshall A Silva M Foley S Cranmer L Wang DJ McColl DJ Kemp RL Coppel, Infect Immun 1997 65 4460 7 9353020
16. Genetic polymorphism in Plasmodium falciparum vaccine candidate antigens. RC Mahajan U Farooq ML Dubey N Malla, Indian J Pathol Microbiol 2005 48 429 38 16366089
17. Lack of sequence diversity in the gene encoding merozoite surface protein 5 of Plasmodium falciparum. T Wu CG Black L Wang AR Hibbs RL Coppel, Mol Biochem Parasitol 1999 103 243 50 10551366
18. Influence of adjuvants on protection induced by a recombinant fusion protein against malarial infection. TM Daly CA Long, Infect Immun 1996 64 2602 8 8698485
19. Escape of malaria parasites from host immunity requires CD4+ CD25+ regulatory T cells. H Hisaeda Y Maekawa D Iwakawa H Okada K Himeno K Kishihara S Tsukumo K Yasutomo, Nat Med 2004 10 29 30 14702631
20. Upregulation of TGF-beta, FOXP3, and CD4+CD25+ regulatory T cells correlates with more rapid parasite growth in human malaria infection. M Walther JE Tongren L Andrews D Korbel E King H Fletcher RF Andersen P Bejon F Thompson SJ Dunachie, Immunity 2005 23 287 96 16169501
21. Regulating immunity to malaria. EM Riley S Wahl DJ Perkins L Schofield, Parasite Immunol 2006 28 35 49 16438675
22. Recent advances in the discovery and delivery of vaccine adjuvants. DT O'Hagan NM Valiante, Nat Rev Drug Discov 2003 2 727 35 12951579
23. Safety and immunogenicity of the RTS,S/AS02A candidate malaria vaccine in children aged 1-4 in Mozambique. E Macete JJ Aponte C Guinovart J Sacarlal O Ofori-Anyinam I Mandomando M Espasa C Bevilacqua A Leach MC Dubois, Trop Med Int Health 2007 12 37 46 17207146
24. Evaluation of two formulations of adjuvanted RTS, S malaria vaccine in children aged 3 to 5 years living in a malaria-endemic region of Mozambique: a Phase I/IIb randomized double-blind bridging trial. EV Macete J Sacarlal JJ Aponte A Leach MM Navia J Milman C Guinovart I Mandomando Y Lopez-Pua M Lievens, Trials 2007 8 11 17386091
25. Development of RTS,S/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. N Garcon DG Heppner J Cohen, Expert Rev Vaccines 2003 2 231 8 12899574
26. Potency assay design for adjuvanted recombinant proteins as malaria vaccines. BK Giersing F Dubovsky A Saul F Denamur P Minor B Meade, Vaccine 2006 24 4264 70 16767804
27. Clinical immunity to malaria. L Schofield I Mueller, Curr Mol Med 2006 6 205 21 16515511
28. Immune responses to liver-stage parasites: implications for vaccine development. MR Hollingdale U Krzych, Chem Immunol 2002 80 97 124 12058653
29. Pre-erythrocytic malaria vaccines: towards greater efficacy. AV Hill, Nat Rev Immunol 2006 6 21 32 16493425
30. Immunoglobulin G antibodies to merozoite surface antigens are associated with recovery from chloroquine-resistant Plasmodium falciparum in Gambian children. M Pinder CJ Sutherland F Sisay-Joof J Ismaili MB McCall R Ord R Hallett AA Holder P Milligan, Infect Immun 2006 74 2887 93 16622227
31. Characterization of the merozoite surface protein 4/5 gene of Plasmodium berghei and Plasmodiumyoelii. L Kedzierski CG Black RL Coppel, Mol Biochem Parasitol 2000 105 137 47 10613706
32. Novel adjuvant based on a proteoliposome-derived cochleate structure containing native lipopolysaccharide as a pathogen-associated molecular pattern. O Perez G Bracho M Lastre N Mora J del Campo D Gil C Zayas R Acevedo D Gonzalez JA Lopez, Immunol Cell Biol 2004 82 603 10 15550118
33. Scale up of proteoliposome derived Cochleate production. C Zayas G Bracho M Lastre D Gonzalez D Gil R Acevedo J del Campo C Taboada RL Solis R Barbera, Vaccine 2006 24 Suppl 2 94 5 16823944
34. Targeting immune response induction with cochleate and liposome-based vaccines. RJ Mannino M Canki E Feketeova AJ Scolpino Z Wang F Zhang MT Kheiri S Gould-Fogerite, Adv Drug Deliv Rev 1998 32 273 287 10837648
35. Proteoliposome derived cochleate as novel adjuvant. G Bracho M Lastre J del Campo C Zayas D Gonzalez D Gil R Acevedo C Taboada RL Solis O Perez, Vaccine 2006 24 Suppl 2 30 1 16823914
36. New vaccines require potent adjuvants like AFPL1 and AFCo1. O Perez M Lastre O Cabrera K del Campo G Bracho M Cuello J Balboa R Acevedo C Zayas D Gil, Scand J Immunol 2007 66 271 7 17635804
37. Immunological evaluation of bacterial derived Cochleate and proteoliposome as mucosal adjuvants. J del Campo M Lastre G Bracho T Rodriguez D Gil C Zayas C Taboada R Acevedo DR Perez O Perez, Vaccine 2006 24 Suppl 2 50 51 16823924
38. Cutaneous delayed-type hypersensitivity (DTH) in a multi-formulation comparator trial of the anti-falciparum malaria vaccine candidate RTS,S in rhesus macaques. VA Stewart DS Walsh SM McGrath KE Kester JF Cummings G Voss M Delchambre N Garcon JD Cohen DG Heppner Jr, Vaccine 2006 24 6493 502 16911849
39. Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02A. VA Stewart SM McGrath DS Walsh S Davis AS Hess LA Ware KE Kester JF Cummings JR Burge G Voss, Vaccine 2006 24 6483 92 16904798
40. Regulation of the CD8+ T cell responses against Plasmodium liver stages in mice. A Morrot F Zavala, Int J Parasitol 2004 34 1529 34 15582529
41. The cross-priming pathway: a portrait of an intricate immune system. S Basta A Alatery, Scand J Immunol 2007 65 311 9 17386021
42. Immunity to recombinant Plasmodium falciparum merozoite surface protein 1 (MSP1): protection in Aotus nancymai monkeys strongly correlates with anti-MSP1 antibody titer and in vitro parasite-inhibitory activity. S Singh K Miura H Zhou O Muratova B Keegan A Miles LB Martin AJ Saul LH Miller CA Long, Infect Immun 2006 74 4573 80 16861644
43. Immune responses to asexual blood-stages of malaria parasites. SS Yazdani P Mukherjee VS Chauhan CE Chitnis, Curr Mol Med 2006 6 187 203 16515510
44. Identification of early cellular immune factors regulating growth of malaria parasites in humans. MF Good, Immunity 2005 23 241 2 16169495
45. Malaria blood-stage infection and its control by the immune system. P Perlmann M Troye-Blomberg, Folia Biol (Praha) 2000 46 210 8 11140853
46. Improved T cell responses to Plasmodium falciparum circumsporozoite protein in mice and monkeys induced by a novel formulation of RTS,S vaccine antigen. P Mettens PM Dubois MA Demoitie B Bayat MN Donner P Bourguignon VA Stewart DG Heppner Jr N Garcon J Cohen, Vaccine 2008 26 1072 82 18258343
47. Oscillations in the immune system. J Stark C Chan AJ George, Immunol Rev 2007 216 213 31 17367345
48. Sustained high-titer antibody responses induced by conjugating a malarial vaccine candidate to outer-membrane protein complex. Y Wu C Przysiecki E Flanagan SN Bello-Irizarry R Ionescu O Muratova G Dobrescu L Lambert D Keister Y Rippeon, Proc Natl Acad Sci USA 2006 103 18243 8 17110440
49. How bacteria and their products provide clues to vaccine and adjuvant development. G Dougan C Hormaeche, Vaccine 2006 24 Suppl 2 13 9 16823909
50. Toll-like receptors: sentinels of host defence against bacterial infection. M Schnare M Rollinghoff S Qureshi, Int Arch Allergy Immunol 2006 139 75 85 16319494
51. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. G Napolitani A Rinaldi F Bertoni F Sallusto A Lanzavecchia, Nat Immunol 2005 6 769 76 15995707
52. Identification of the Plasmodium chabaudi homologue of merozoite surface proteins 4 and 5 of Plasmodium falciparum. CG Black L Wang AR Hibbs E Werner RL Coppel, Infect Immun 1999 67 2075 81 10225857
53. Merozoite surface protein 4/5 provides protection against lethal challenge with a heterologous malaria parasite strain. MW Goschnick CG Black L Kedzierski AA Holder RL Coppel, Infect Immun 2004 72 5840 9 15385485
54. Immunization with a combination of merozoite surface proteins 4/5 and 1 enhances protection against lethal challenge with Plasmodium yoelii. L Kedzierski CG Black MW Goschnick AW Stowers RL Coppel, Infect Immun 2002 70 6606 13 12438332